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ABSTRACT 
 
Objectives: Spondyloarthritis (SpA) is associated with a number of cardiovascular comorbidities. We 
examined the association of SpA disease duration and delay in diagnosis with cardiovascular-related 
conditions. 
Methods: Using data from the COMOSPA study, the associations between “SpA disease duration” and 
cardiovascular-related conditions were evaluated in univariable and multivariable logistic regression 
models. Each model examined one cardiovascular-related factor as dependent and “SpA disease 
duration” as predictor, adjusted for relevant confounders.  
Results: Data from 3923 subjects (median (IQR) SpA disease duration 5.1 (1.3 – 11.8) years) were 
available for analysis. The main cardiovascular-related conditions were hypertension (22.4%), 
ischaemic heart disease (2.6%), stroke (1.3%) and diabetes mellitus (5.5%).  Hypertension (“ever 
diagnosis”) was associated with SpA disease duration in both univariable and multivariable analysis, 
with an odds-ratio (OR) of 1.129 (95% CI: 1.072-1.189; p<0.001) for each 5-year increase in SpA disease 
duration. Other factors associated with hypertension were age, male gender, current BMI, ever steroid 
therapy and ever synthetic DMARDs therapy, but not NSAIDs. In subgroup analysis, the strongest 
association of hypertension and disease duration was seen in subjects with axial-only SpA phenotype 
(OR=1.202, 95%CI: 1.053-1.372) but not in those with peripheral-only SpA (OR=0.902, 95%CI: 0.760-
1.070). The other cardiovascular conditions were not associated with SpA disease duration. 
Conclusion: Duration of SpA disease in the ASAS-COMOSPA cohort is associated with higher risk of 
hypertension, particularly in those with axial disease, but not with other cardiovascular-related 
conditions. The association with hypertension does not appear to be related to NSAID exposure. 
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INTRODUCTION  
Spondyloarthritis (SpA) encompasses a number of related inflammatory conditions, characterized by 
considerable overlap in clinical features reflecting their shared genetic susceptibility and 
pathophysiology (1–7). In common with other chronic inflammatory diseases such as rheumatoid 
arthritis (RA), SpA  is associated with an increased risk of cardiovascular comorbidity and increased 
mortality when compared to the general population (8–10). This association is incorporated in 
treatment guidelines, with specific recommendations to monitor and prevent cardiovascular disease 
(11–15). However, many of these recommendations are adapted from RA where this increased risk is 
better understood (15) and appears to be predominantly related to systemic inflammatory burden, 
with accumulating evidence for a reduction in cardiovascular events in patients whose RA improves 
with a range of immunomodulatory treatments (16–19).  By contrast, the inflammatory burden in SpA 
is significantly lower than in RA, with many SpA patients having a normal acute phase. Over the past 
decade, it has become recognised that, in keeping with their pathophysiological differences, there 
appear to be differences in the prevalence and type of cardiovascular-related comorbidities seen in 
RA and SpA. For example, the prevalence of major cardiac events (MACEs) appears to be lower in 
patients with ankylosing spondylitis (AS; also termed radiographic axial SpA) than those with RA 
(20,21). In turn, AS is associated with an increased risk of hypertension, while psoriatic arthritis (PsA) 
is associated with increased diabetes and metabolic syndrome (22–24). These comorbidities have 
traditionally been studied in patients with distinct SpA sub-groups, but in clinical practice, the 
distinction is often less clear and phenotypes often overlap.  
 
The ASAS-COMOSPA study is a large, global study designed to evaluate comorbidities in patients with 
SpA (27). Initial analysis indicated that the most frequent cardiovascular-related condition observed 
in this population is hypertension, although there is significant geographic variation in comorbidities 
(27). However, it is not clear whether this increased risk relates to the disease itself, its treatments 
(particularly NSAIDs and corticosteroids) or other factors. Although determining causality would 
require large prospective long-term studies, the ASAS-COMOSPA cohort offers an opportunity to 
explore some of these associations in more detail. The aim of the current report was to evaluate the 
association of disease duration and delay in diagnosis with the development of cardiovascular-related 
comorbidities and risk factors in SpA subjects within the ASAS-COMOSPA cohort. 
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METHODS & MATERIALS 
Study design 
The current report is an analysis of data from the COMOSPA multicentre and international cross-
sectional study, with 22 participating countries throughout five continents (Africa, Asia, Europe, North 
and South America) as previously reported (27). Briefly, consecutive adult patients attending 
participating centres who met the ASAS classification criteria (either axial or peripheral) for SpA 
according to the treating rheumatologist were included (25,26). All information was obtained at a 
study visit by the study investigator or research nurse during a face-to-face interview with the 
participant, combined with review of the medical record. In addition to the study visit date, the date 
of diagnosis and, where relevant, date(s) of first musculoskeletal symptoms (back pain, peripheral 
joint symptoms, enthesitis or dactylitis) were captured. The following cardiovascular-related 
comorbidities and risk factors were recorded: ever diagnosis of hypertension, ischaemic heart disease 
(IHD), stroke, diabetes mellitus and dyslipidaemia.  
As described in the original COMOSPA study (27), in each participant country, consecutive adult 
patients who were able to understand and complete questionnaires were included. The study was 
conducted according to guidelines for good clinical practice in all countries. Written informed consent 
was obtained from all sub-jects before enrolment.  
 
 
Data analysis 
Central tendencies in each group are presented by median and interquartile range, unless otherwise 
stated. Where necessary, the differences between independent groups were examined using Mann 
Whitney U test. In order to explore the association between SpA chronology and cardiovascular-
related conditions, a number of new time variables were created: first, “SpA Disease Duration” was 
defined as the period between age at diagnosis of SpA and the date of completing the survey. 
Secondly, the “Delay in SpA Diagnosis” was defined as the time gap between the first musculoskeletal 
symptoms of SpA (i.e. the earliest report of back pain, peripheral joint pain, enthesitis or dactylitis) 
and the diagnosis of SpA (See Supplementary Figure 1).  
 
The association between SpA disease duration (defined in 5-year blocks) and cardiovascular-related 
conditions was examined using univariable and multivariable binary logistic regression. Each model 
comprised one cardiovascular-related condition as dependent and SpA disease duration as predictor 
adjusted for relevant co-founders in two stages of adjustments. In the first stage (partial adjustment), 
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confounders were age (continuous), sex (reference: females), current BMI (continuous), history of 
smoking (pack-year), alcohol (reference: non-drinker), ever use of NSAIDs (reference: none), ever use 
of steroids (reference: none), ever use of synthetic DMARDs (reference: none), ever use of biological 
DMARDs (reference: none), other relevant factors and interaction terms, if necessary. Thereafter (full 
adjustment), the model also included the delay in SpA diagnosis (defined in single years due to the 
shorter duration than SpA disease duration) in addition to all the factors used earlier. The magnitude 
of the associations is presented using Wald statistics, odds ratios and relevant 95% confidence 
intervals. Potential collinearity was tested using correlation matrix, tolerance and variation inflation 
factors (VIF) in a linear regression model. All significance levels set to a p value less than 0.05. 
 
Where positive associations were identified, patients were stratified depending on whether their joint 
involvement was axial, peripheral or mixed. Axial involvement was defined as the clinicians’ report in 
the dataset of “ever suffered from inflammatory chronic (at least 3 months) back pain starting before 
the age of 45 years”, while peripheral involvement was defined as the presence of “ever suffered from 
peripheral joint disease/symptoms suggestive of enthesitis/dactylitis”.  
 
 
 
 
 
RESULTS 
A) Demographic and disease characteristics 
A total of 3,923 participants had suitable data for analysis. A small proportion (1.5%) were excluded 
due to age less than 18 years (n=41), missing date of visit (n=15), missing date of birth (n=4) and 
missing date of birth and date of visit (n=1).  
 
Baseline demographics showed an age range of 18 to 100, with a median (IQR) of 42 (32-53) years; 
64.9% (n=2,547) were male. Female patients were significantly older than males [median (IQR): 44.0 
(19.0) vs 41.0 (21.0), p<0.001]. Median BMI was 25.3 (IQR: 6.2). Almost a quarter (23.0%) of the 
patients were current smokers, 23.4% were ex-smokers and 53.6% had never smoked. Regarding 
alcohol consumption, 47.8% of patients reported drinking no alcohol, 7.5% were ex-drinkers, 37.5% 
currently drink less than 3 units/day, and only 6.7% currently drink 3 units or more /day. 
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The median (IQR) age at SpA diagnosis was 33 (25.0 – 43.0) years while the median (IQR) age at which 
the first musculoskeletal symptom(s) of SpA appeared was 29.4 (21.9 – 39.9) for the entire group 
(Figure 1). The estimated median (IQR) SpA disease duration was 5.1 (1.3 – 11.8) years and the 
estimated median (IQR) delay in SpA diagnosis was 1.1 (0.0 – 5.9) years. 
 
B) Cardiovascular-related conditions 
The prevalence of the main cardiovascular-related conditions assessed were: ever diagnosis of 
hypertension in 872 (22.4%), ever diagnosis of IHD in 102 (2.6%), ever diagnosis of stroke in 50 (1.3%), 
ever diagnosis of diabetes in 215 (5.5%) and ever diagnosis of dyslipidaemia in 643 (16.6%).  
 
C) Association of SpA Disease Duration with Hypertension 
An association between the risk of hypertension and SpA disease duration was found in both 
univariable, and multivariable models (Table 1), the latter conducted with partial and full adjustment. 
In the partial adjustment model, the risk was calculated taking into account the possible effects and 
interactions of all main confounders, but without considering the effect of delay in SpA diagnosis. This 
model showed a statistically significant association between SpA disease duration and hypertension 
(OR= 1.11, 95% CI: 1.06 – 1.16) (Supplementary Table 1).  The full adjustment model included a further 
adjustment for delay in SpA diagnosis (Table 1 lower rows) and indicated that the risk of having a 
diagnosis of hypertension increased by 13% per each 5-year increase in the duration of SpA (OR= 1.13, 
95% CI: 1.07 – 1.19; p<0.001) (Figure 1). 
 
Confounding variables with significant association with hypertension were: delay in SpA diagnosis 
(OR=1.01, 95%CI: 1.00 – 1.02; p=0.033), current age (OR=1.09, 95% CI: 1.08 - 1.10; p<0.001), male 
gender (OR=1.44, 95%CI: 1.17 - 1.77; p<0.001), current BMI (OR=1.09, 95% CI: 1.07 - 1.11; p<0.001), 
ever use of steroids (OR=1.23, 95% CI: 1.01 - 1.50; p=0.038) and ever use of synthetic DMARDs 
(OR=1.34, 95% CI: 1.09 - 1.66; p=0.006), but not ever use of NSAIDs or biologic DMARDs (Table 1). 
  
D) Association of SpA Disease Duration with Hypertension in SpA subgroups     
In order to evaluate whether the association was generalised for SpA or related to joint distribution, 
participants were stratified into those with axial disease only, peripheral disease only, mixed axial and 
peripheral disease, any axial disease (axial only plus mixed) and any peripheral (peripheral disease 
only plus mixed) (Supplementary Figure 2). Stratification by SpA subgroup indicated a stronger 
association was found in the “axial only” subgroup (OR=1.20, 95% CI: 1.05 - 1.37, p<0.001) compared 
to “peripheral only” subgroup (OR=0.90, 95% CI: 0.76 - 1.07, p=0.237) (Table 2). Similarly, comparing 
the “any axial” subgroup to “any peripheral” subgroup showed a slightly stronger risk of hypertension 
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in the former group. The results in “mixed” axial and peripheral subgroup were comparable to that of 
entire cohort (Table 2).  
Analyses of associations with partial adjustments (all confounders excluding delay in SpA diagnosis) 
produced similar estimates to those for the full adjustment models. 
 
 
E) Association of Delay in SpA Diagnosis with Hypertension 
There was a weak but marginally significant association between hypertension and the delay in SpA 
diagnosis (OR=1.01, 95% CI: 1.00 - 1.02; p=0.033) in the entire cohort, indicating a 1% increase in the 
risk of hypertension for each year of delay in SpA diagnosis (Table 1; Figure 1). Stratifying the results 
by SpA subgroups revealed that the association was largest in the “any axial” (OR=1.02, 95% CI: 1.01 - 
1.03; p=0.004) and “mixed axial and peripheral” subgroups (OR=1.02, 95% CI: 1.01 - 1.03; p=0.002) 
(Table 2).  
 
F) Associations of SpA Disease Duration with Other Cardiovascular-related Conditions 
Other cardiovascular-related conditions including IHD, stroke, diabetes mellitus and dyslipidaemia 
were incorporated to logistic regression models, adjusting for relevant confounders (Tables 3 to 6 and 
summarised in Figure 1) with no associations found with SpA disease duration, in either univariable or 
multivariable models. Similarly, delay in SpA diagnosis was not associated with any of these conditions 
(Tables 3-5, Suppl.Table 2 and Figure 1).  
 
DISCUSSION 
The large COMOSPA cohort has allowed for the evaluation of the association of a number of 
cardiovascular-related conditions with disease duration across the spectrum of SpA. In this analysis, 
we found that hypertension was associated with increased SpA disease duration and delay in SpA 
diagnosis, even when adjusted for other confounding factors. This association was stronger in patients 
with axial disease than in those with peripheral disease. There was no association of SpA disease 
duration with IHD, stroke, diabetes mellitus or dyslipidaemia. 
 
The association of cardiovascular comorbidities with inflammatory rheumatic conditions is well 
recognised and widely quoted (11,12,14,15,28). However, most of the data come from RA, which is 
characterised by high levels of systemic inflammation and where successful reduction in inflammation 
through treatment with biologics and methotrexate, but not corticosteroids or NSAIDs, is associated 
with reduced cardiovascular risk (16–19). By contrast, this association is not as clear in SpA, where 
there are fewer, smaller studies with significant heterogeneity in results (20,29). Several reports have 
suggested that, when appropriately adjusted for age and gender, the risk of MACEs in PsA and AS may 
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be less than in RA (20,30,31). In fact, in several AS studies, the lower limit of the 95% confidence 
interval for the risk of IHD was 1.0 or less (20,21,32), whereas others report IHD rates similar to RA 
(33–35).  
 
The differences in reported rates of MACEs associated with PsA and AS relate to a number of factors, 
including cohort size, the definition of disease used and adjustment for confounding factors. Age and 
gender are particularly important as patients with AS are more likely to be male (therefore already at 
increased risk for cardiovascular disease) and develop disease at a younger age, so will have had a 
longer duration of disease by a specified age than patients with RA. Almost two-thirds (65%) of the 
COMOSPA participants were male, with a median age at SpA diagnosis of 33 years and estimated 
median SpA disease duration of 5.1 years. 
 
Cross sectional studies can only indicate association and do not imply causality. Attempts have been 
made to evaluate a possible dose-response relationship between the rheumatic inflammatory burden 
and the risk of cardiovascular disease. Although there is some evidence to suggest this may also be 
the case in SpA (38–40), this association is difficult to assess as many of the disease activity measures 
(eg BASDAI) are subjective and acute phase reactants often do not reflect disease activity.  
 
Cardiovascular-related conditions generally take many years or decades to develop and become 
evident, so the duration of the underlying SpA disease offers an alternative way to further evaluate 
the association of these conditions as it represents the cumulative amount of time the patient has had 
the disease, and any therapies for this, and therefore represents a surrogate of the SpA disease 
burden. The delay from symptom onset to SpA diagnosis represents the period without diagnosis or 
specific therapy. In this study, we found that neither the length of SpA disease duration nor the delay 
in diagnosis were associated with the risk of developing IHD, stroke, diabetes mellitus or 
dyslipidaemia.  
 
In contrast, we found that the longer the SpA disease duration, the higher the risk of developing 
hypertension (OR 1.13 for every 5 years of SpA disease duration). Furthermore, delay in SpA diagnosis 
was associated with a small increase in hypertension (OR 1.01 for every year of delay in SpA diagnosis; 
5% increased risk for every 5 years of delay). This increased risk was highest in those patients with 
axial disease and remained significant, even when corrected for age, gender and other confounding 
factors. Previous publications have suggested that SpA conditions, particularly AS, are associated with 
an increased risk of hypertension (20,21,41–43). The mechanism for this association is currently 
unclear. NSAIDs are known to increase blood pressure (44,45) and remain the mainstay of treatment 
in axSpA (28), while patients with PsA have an increased risk of metabolic syndrome (22–24). 
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Interestingly, NSAIDs were not associated with an increased risk of hypertension in this cohort. This 
may be because almost 90% of participants received NSAIDs at some stage for their symptoms, with 
no adjustment possible for cumulative dose. Two-thirds (67.8%) of participants had taken NSAIDs 
within the three months prior to the study assessment. It is also likely that in clinical practice, NSAIDs 
were avoided or stopped in patients with existing hypertension.  Our data therefore suggest that 
longer SpA disease duration is associated with an increased risk of developing hypertension, but not 
IHD or stroke. 
 
The study results must be interpreted in the context of the study limitations. COMOSPA is a cross-
sectional study and included self-reported data, which may incur recall bias. However, the clinical staff 
corroborated the information using the participant’s medical records. The prevalence of hypertension 
in this paper (22.4%) cannot be compared to the prevalence reported in the earlier COMOSPA paper 
(33.5%) as a different definition of hypertension were used (27). We defined hypertension as “ever 
diagnosis of hypertension”, as we wanted to only include participants with confirmed hypertension, 
whereas the previous paper used a broader definition, which included the current blood pressure 
reading and history of any antihypertensive medication (27). Similarly, for diabetes mellitus and 
dyslipidaemia, we also used only “ever diagnosis of” and not the current glucose or lipid levels, 
respectively, as these were not fasting, and these data fields contained significant missing data, 
although sensitivity analysis did not reveal any significant difference (data not shown). The study 
format did not capture the date of onset of hypertension, so it is not possible to comment on the 
timing relative to the SpA disease course.  The study design did not rigorously capture cumulative dose 
or duration of NSAIDs, so this could not be assessed in the analysis and we were limited to using “ever 
use of NSAIDs”. Patients with IHD or stroke may have been unable to attend clinics or have died, so 
would not be captured in study selection, leading to underestimation of these comorbidities. The 
participants were recruited from secondary care clinics, so may not be representative of the wider 
population of patients with SpA. The impact of this is likely to vary between countries, with global 
variation in comorbidities evaluated in other COMOSPA-related analyses.  
 
In summary, this study suggests an increased risk of hypertension with longer SpA disease duration, 
particularly in patients with axial disease, which is not related to NSAID use. Interestingly, disease 
duration was not associated with an increased risk of the other cardiovascular-related conditions in 
this cohort, adding further support to the growing literature suggesting there are differences in 
cardiovascular-related comorbidities between RA and SpA. Blood pressure measurement is a simple, 
feasible procedure which should be regularly checked in patients with SpA in the clinical setting, 
particularly in those with longer disease duration.  
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Table 1: Association between SpA Disease Duration and Hypertension, adjusted for all relevant 
confounders including Delay in SpA Diagnosis; entire cohort 
All Wald p value OR 95% CI for OR 
     Univariable     
SpA Disease duration (5y blocks) 253.050 <0.001 1.387 1.332 - 1.444 
     Multivariable     
SpA Disease duration (5y blocks) 21.031 <0.001 1.129 1.072 - 1.189 
Delay in SpA Diagnosis 4.521 0.033 1.012 1.001 - 1.023 
Age (year) 360.371 <0.001 1.089 1.080 - 1.099 
Gender (ref: Female) 12.196 <0.001 1.442 1.174 - 1.771 
Current BMI 108.154 <0.001 1.089 1.072 - 1.107 
Smoking (pack-year) 0.017 0.895 1.000 0.993 - 1.006 
Alcohol (ref: Never) 5.613 0.132   
   Ex-drinker 0.838 0.360 1.185 0.824 - 1.706 
   Current, <3 Units 2.848 0.092 0.835 0.678 - 1.029 
   Current, >=3 Units 1.353 0.245 0.794 0.539 - 1.171 
Ever use of NSAIDs  0.514 0.473 1.125 0.816 - 1.551 
Ever use of Steroids 4.308 0.038 1.231 1.012 - 1.497 
Ever use of Synthetic DMARDs 7.451 0.006 1.341 1.086 - 1.655 
Ever use of Biologic DMARDs 0.244 0.622 1.050 0.866 - 1.272 
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Table 2: Association between hypertension and SpA Disease Duration or Delay in SpA Diagnosis in 
entire group and subgroups of SpA (Multivariable) 
 Group N 
 
Wald p value OR 95% CI for OR 
 SpA Disease Duration (5-year blocks)1       
 Entire group 3923  21.031 <0.001 1.129 1.072 - 1.189 
     Any Axial 3393  29.471 <0.001 1.170 1.106 - 1.239 
     Any Peripheral 2688  12.591 <0.001 1.109 1.047 - 1.174 
     Axial only  1138  7.393 0.007 1.202 1.053 - 1.372 
     Peripheral only 434  1.397 0.237 0.902 0.760 - 1.070 
     Mixed Axial & Peripheral 2254  20.240 <0.001 1.158 1.086 - 1.234 
 Delay in SpA Diagnosis2       
 Entire group 3923  4.521 0.033 1.012 1.001 - 1.023 
     Any Axial   3393  8.397 0.004 1.017 1.006 - 1.029 
     Any Peripheral   2688  5.019 0.025 1.013 1.002 - 1.025 
     Axial only   1138  0.321 0.571 1.008 0.980 - 1.038 
     Peripheral only    434  1.026 0.311 0.978  0.936 - 1.021 
     Mixed Axial & Peripheral 2254  9.420 0.002 1.020 1.007 - 1.033 
 
Note: 1: The model adjusted to potential confounders including age, gender, BMI, smoking, alcohol 
consumption, ever use of NASIDs, ever use of steroids, ever used of synthetic DMARDs, ever use of biologic 
DMARDs, and Delay in SpA diagnosis; 2: adjusted to all above factors, including SpA disease duration but not 
Delay in SpA diagnosis. 
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Table 3: Association between SpA Disease Duration and Ischaemic Heart Disease, adjusted for all 
relevant confounders including Delay in SpA Diagnosis; entire cohort 
All Wald p value OR 95% CI for OR 
     Univariable     
SpA Disease Duration (5y blocks) 55.447 <0.001 1.333 1.236 - 1.438 
     Multivariable     
SpA Disease Duration (5y blocks) 0.142 0.706 1.019 0.925 - 1.123 
Delay in SpA Diagnosis 0.059 0.808 1.003 0.982 - 1.024 
Age (year) 50.129 <0.001 1.079 1.056 - 1.101 
Gender (ref: Female) 6.710 0.010 2.100 1.198 - 3.681 
Current BMI 1.430 0.232 1.023 0.986 - 1.062 
Smoking (pack-year) 4.540 0.033 1.013 1.001 - 1.024 
Alcohol (ref: Never) 1.201 0.753   
   Ex-drinker 0.104 0.747 1.140 0.515 - 2.524 
   Current, <3 Units 0.478 0.489 0.835 0.500 - 1.393 
   Current, >=3 Units 0.546 0.460 0.713 0.291 - 1.747 
Ever use of NSAIDs 0.450 0.502 1.301 0.603 - 2.807 
Ever use of Steroids 1.597 0.206 1.353 0.847 - 2.161 
Ever use of Synthetic DMARDs 2.675 0.102 1.564 0.915 - 2.673 
Ever use of Biologic DMARDs 0.108 0.742 1.081 0.679 - 1.722 
Ever Dx of HTN 25.855 <0.001 4.436 2.498 - 7.877 
Ever Dx of Diabetes 13.868 <0.001 2.774 1.621 - 4.745 
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Table 4: Association between SpA Disease Duration and Stroke, adjusted for all relevant 
confounders including Delay in SpA Diagnosis; entire cohort 
All Wald p value OR 95% CI for OR 
     Univariable     
SpA Disease Duration (5y blocks) 20.107 <0.001 1.287 1.153 - 1.437 
     Multivariable     
SpA Disease Duration (5y blocks) 0.001 0.979 0.998 0.865 - 1.151 
Delay in SpA Diagnosis 0.102 0.749 1.005 0.975 - 1.036 
Age (year) 6.969 0.008 1.042 1.011 - 1.074 
Gender (ref: Female) 0.004 0.952 0.978 0.472 - 2.025 
Current BMI 0.495 0.482 0.980 0.925 - 1.037 
Smoking (pack-year) 5.121 0.024 1.017 1.002 - 1.033 
Alcohol (ref: Never) 1.405 0.704   
   Ex-drinker 0.184 0.668 0.750 0.201 - 2.796 
   Current, <3 Units 0.268 0.605 1.202 0.598 - 2.417 
   Current, >=3 Units 0.551 0.458 0.561 0.122 - 2.578 
Ever use of NSAIDs 0.126 0.723 1.219 0.408 - 3.644 
Ever use of Steroids 0.396 0.529 0.804 0.408 - 1.586 
Ever use of Synthetic DMARDs 2.222 0.136 0.593 0.298 - 1.179 
Ever use of Biologic DMARDs 0.019 0.891 1.046 0.546 - 2.006 
Ever Dx of HTN 21.433 <0.001 8.843 3.514 - 22.252 
Ever Dx of Diabetes 2.173 0.140 1.843 0.817 - 4.156 
FHx of MI 6.436 0.011 0.423 0.217 - 0.822 
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Table 4: Association between SpA Disease Duration and Stroke, adjusted for all relevant 
confounders including Delay in SpA Diagnosis; entire cohort 
All Wald p value OR 95% CI for OR 
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Table 5: Association between SpA Disease Duration and Diabetes, adjusted for all relevant 
confounders including Delay in SpA Diagnosis; entire cohort 
All Wald p value OR 95% CI for OR 
     Univariable     
SpA Disease Duration (5y blocks) 27.441 <0.001 1.184 1.112 - 1.262 
     Multivariable     
SpA Disease Duration (5y blocks) 1.867 0.172 0.943 0.868 - 1.026 
Delay in SpA Diagnosis 0.440 0.507 0.994 0.977 - 1.012 
Age (year) 41.189 <0.001 1.050 1.035 - 1.066 
Gender (ref: Female) 5.254 0.022 1.543 1.065 - 2.235 
Current BMI 63.528 <0.001 1.095 1.071 - 1.120 
Smoking (pack-year) 0.095 0.757 1.002 0.991 - 1.012 
Alcohol (ref: Never) 14.507 0.002   
   Ex-drinker 0.109 0.742 1.100 0.625 - 1.935 
   Current, <3 Units 12.746 <0.001 0.492 0.333 - 0.726 
   Current, >=3 Units 0.729 0.393 0.750 0.388 - 1.450 
Ever use of NSAIDs 0.170 0.680 0.897 0.534 - 1.506 
Ever use of Steroids 0.369 0.544 1.111 0.791 - 1.561 
Ever use of Synthetic DMARDs 0.521 0.471 1.149 0.788 - 1.677 
Ever use of Biologic DMARDs 1.862 0.172 1.263 0.903 - 1.768 
Ever Dx of HTN 52.893 <0.001 4.067 2.787 - 5.936 
Ever Dx of Stroke 1.944 0.163 1.757 0.796 - 3.881 
FHx of MI 3.712 0.054 0.695 0.480 - 1.006 
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Supplementary Figures and Tables: 
 
Supplementary Figure 1: Definition of “SpA Duration of Disease” and “Delay in SpA Diagnosis” terms 
used in the study 
 
Supplementary Figure 2: Subgroups of SpA based on joint distribution 
 
Supplementary. Table 1:  Association between SpA Disease Duration and Hypertension, partially-
adjusted for all relevant confounders; entire cohort 
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Supplementary Figure 1: Definition of “SpA Duration of Disease” and “Delay in SpA Diagnosis” terms 
used in the study 
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Supplementary Figure 2: Subgroups of SpA based on joint distribution 
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Supplementary Table 1:  Association between SpA Disease Duration and Hypertension, partially-
adjusted for all relevant confounders; entire cohort 
All Wald p value OR 95% CI for OR 
       Univariable     
  Disease duration (5y blocks) 267.839 <0.001 1.392 1.338 - 1.448 
       Multivariable     
  Disease duration (5y blocks) 17.785 <0.001 1.109 1.057 - 1.164 
  Age (year) 432.227 <0.001 1.093 1.084 - 1.102 
  Gender (ref: Female) 13.591 <0.001 1.462 1.195 - 1.790 
  Current BMI 112.437 <0.001 1.090 1.072 - 1.107 
  Smoking (pack-year) 0.000 1.000 1.000 0.994 - 1.007 
  Alcohol (ref: Never) 3.715 0.294   
     Ex-drinker 1.094 0.296 1.206 0.849 - 1.712 
     Current, <3 Units 1.408 0.235 0.884 0.720 - 1.084 
     Current, >=3 Units 0.464 0.496 0.879 0.605 - 1.275 
  Ever use of NSAIDs  1.001 0.317 1.173 0.858 - 1.602 
  Ever use of Steroids 4.790 0.029 1.239 1.023 - 1.500 
  Ever use of Synthetic DMARDs 5.849 0.016 1.284 1.049 - 1.573 
  Ever use of Biologic DMARDs 0.532 0.466 1.072 0.889 - 1.293 
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Supplementary Table 2: Association between SpA Disease Duration and Dyslipidaemia, adjusted 
for all relevant confounders including Delay in SpA Diagnosis; entire cohort 
All Wald p value OR 95% CI for OR 
     Univariable     
SpA Disease Duration (5y blocks) 102.593 <0.001 1.242 1.191 - 1.295 
     Multivariable     
SpA Disease Duration (5y blocks) 0.006 0.938 0.998 0.944 - 1.055 
Delay in SpA Diagnosis 0.090 0.764 0.998 0.986 - 1.010 
Age (year) 82.217 <0.001 1.044 1.035 - 1.054 
Gender (ref: Female) 3.555 0.059 1.243 0.991 - 1.559 
Current BMI 14.153 <0.001 1.034 1.016 - 1.052 
Smoking (pack-year) 1.387 0.239 1.004 0.997 - 1.011 
Alcohol (ref: Never) 1.210 0.751   
   Ex-drinker 0.514 0.473 1.157 0.777 - 1.722 
   Current, <3 Units 0.841 0.359 1.113 0.885 - 1.401 
   Current, >=3 Units 0.003 0.956 0.988 0.645 - 1.513 
Ever use of NSAIDs 8.701 0.003 1.764 1.210 - 2.572 
Ever use of Steroids 0.716 0.397 1.097 0.886 - 1.358 
Ever use of Synthetic DMARDs 17.278 <0.001 1.653 1.304 - 2.096 
Ever use of Biologic DMARDs 2.770 0.096 1.195 0.969 - 1.474 
Ever Dx of HTN 81.697 <0.001 2.893 2.298 - 3.642 
Ever Dx of Stroke 43.131 <0.001 3.319 2.320 - 4.748 
FHx of MI 4.408 0.036 2.132 1.052 - 4.324 
Ever Dx of Diabetes 7.695 0.006 1.428 1.110 - 1.837 
 
 
 
 
 
 
